Dorsomorphin (Compound C): Precision AMPK Inhibition in Research

Principle and Setup: Unpacking the Mechanistic Core

Dorsomorphin, widely recognized as Compound C, is a potent, reversible, ATP-competitive AMPK inhibitor (Ki = 109 nM) that has revolutionized the manipulation of energy-sensing and differentiation pathways in cellular models. It achieves high selectivity for AMPK over kinases such as protein kinase A, protein kinase C, and Janus kinase 3, ensuring targeted disruption of the AMPK signaling pathway without off-target effects that could confound data interpretation.

Functionally, Dorsomorphin (Compound C) acts as a dual-pathway modulator: it suppresses AMPK-driven phosphorylation (notably of acetyl-CoA carboxylase, ACC) by up to 80%, curtails autophagic proteolysis, and simultaneously inhibits BMP/Smad signaling—specifically BMP4-induced SMAD 1/5/8 phosphorylation (IC₅₀ = 0.47 μM). This unique profile enables researchers to interrogate both metabolic and developmental signals within the same experimental framework. The compound's utility spans from basic dissection of inhibition of AMPK activity in hepatocytes to advanced studies on neural induction and iron metabolism modulation.

Step-by-Step Workflow: Protocol Enhancements for Reliable Results

1. Compound Preparation

• Solubilization: Dorsomorphin (Compound C) is insoluble in water and ethanol. Dissolve in DMSO at concentrations ≥8.49 mg/mL, using gentle warming (37°C) and ultrasonic treatment for full dissolution. Prepare fresh solutions for each experiment, as long-term storage of solutions is not recommended. Store the solid at -20°C.
• Aliquoting: To minimize freeze-thaw cycles, aliquot the DMSO stock into single-use volumes.

2. Cell-Based Assays

• AMPK Inhibition: Treat hepatocytes or HeLa cells with Dorsomorphin at 4–40 μM, depending on cell type sensitivity and experimental endpoint. For robust inhibition of AMPK activity and downstream ACC phosphorylation, 10 μM is a common starting point.
• BMP/Smad Pathway Dissection: For inhibition of BMP4-induced SMAD phosphorylation, use 1–10 μM, titrating to cell context. Monitor phospho-Smad 1/5/8 by immunoblotting to confirm effective pathway blockade.
• Neural Induction/Stem Cell Differentiation: In human embryonic stem cell cultures, Dorsomorphin is commonly combined with other pathway inhibitors to promote neural fate by blocking BMP signaling. Use at 2–5 μM in conjunction with dual-SMAD inhibition protocols.
• Autophagy Regulation: Assess autophagic flux by monitoring LC3-II accumulation (immunoblotting) and autolysosome formation (immunofluorescence) after Dorsomorphin exposure.

3. Animal Studies

• For iron metabolism modulation or in vivo BMP/Smad inhibition, administer 10 mg/kg via intraperitoneal injection. Monitor serum iron and hepatic hepcidin mRNA by qPCR or ELISA.
• For developmental studies, such as dorsalization in zebrafish embryos, microinject or add to embryo water at established concentrations from the literature (commonly 10–40 μM).

4. Experimental Controls

• Include DMSO vehicle controls at identical concentrations used for Dorsomorphin.
• When dissecting dual-pathway effects, combine with pathway-selective agonists/antagonists (e.g., AICAR or BMP4) to validate specificity.

Advanced Applications and Comparative Advantages

As highlighted in recent literature, Dorsomorphin (Compound C) stands out for its ability to decouple intertwined metabolic and developmental signals. For example, the 2024 EMBO Reports study on Wnt-driven bone formation underscores the importance of metabolic rewiring (such as O-GlcNAcylation and glycolytic flux) in osteoblastogenesis—processes tightly linked to both AMPK and BMP signaling. By selectively inhibiting AMPK, researchers can parse out its contributions to energy metabolism and protein modification cascades during osteogenic differentiation, complementing genetic or pharmacological manipulations of the Wnt or BMP pathways.

Key advanced use-cases include:

• Dissecting Metabolic-Epigenetic Interplay: Use Dorsomorphin to modulate ACC phosphorylation and glycolytic flux, then couple with proteomic or metabolic profiling to map downstream effects in stem cell fate or cancer research models.
• Autophagy and Mitophagy Studies: As extensively discussed in "Dorsomorphin (Compound C): AMPK Inhibition and Mitochondrial Quality Control", Dorsomorphin enables controlled inhibition of AMPK-mediated autophagy, providing a clean readout in studies of muscle atrophy, cancer cell survival, or neurodegeneration.
• Dual-Pathway Manipulation: Unlike single-pathway antagonists, Dorsomorphin's ability to inhibit both AMPK and BMP/Smad signaling allows for integrated studies on neural stem cell differentiation, as detailed in "Dorsomorphin (Compound C): Precision AMPK Inhibition for Translational Research". This duality is particularly valuable in protocols requiring precise control over both metabolic state and developmental cues.
• Iron Metabolism Modulation: In hepatocyte and animal models, Dorsomorphin's suppression of BMP signaling reduces hepatic hepcidin expression, leading to increased serum iron—a critical tool for unraveling iron homeostasis in disease contexts.

Compared to genetic knockdowns or less selective chemical inhibitors, Dorsomorphin (Compound C) offers rapid, reversible, and tunable modulation, reducing compensatory effects and facilitating temporal studies.

Troubleshooting and Optimization Tips

• Compound Solubility: If Dorsomorphin fails to dissolve, verify DMSO quality and apply gentle warming (up to 37°C) with brief sonication. Avoid water or ethanol, as solubility is negligible.
• Cytotoxicity: At concentrations >40 μM, off-target toxicity may confound results. Always titrate to the minimal effective dose for pathway inhibition, and include cell viability assays (e.g., MTT, CellTiter-Glo) in initial setup.
• Pathway Specificity: Confirm pathway inhibition by monitoring phospho-ACC (for AMPK) and phospho-Smad1/5/8 (for BMP/Smad). When results are ambiguous, use orthogonal inhibitors or activators as controls.
• Batch Variability: Dorsomorphin is light and temperature sensitive. Store powder at -20°C, desiccated and protected from light. Discard solutions after use; do not freeze-thaw DMSO stocks repeatedly.
• Reproducibility: Document lot number, preparation date, and handling conditions in all protocols. For multicenter studies, harmonize compound source and preparation to minimize inter-lab variability.

Future Outlook: Dorsomorphin as a Platform for Next-Generation Pathway Dissection

The versatility of Dorsomorphin (Compound C) continues to fuel innovation in fields from metabolic disease to developmental biology. Emerging research, such as the EMBO Reports article on Wnt signaling and bone formation, highlights the need for chemical tools capable of precise, multi-pathway modulation—an area where Dorsomorphin excels. As new post-translational modifications (e.g., O-GlcNAcylation) and metabolic-epigenetic axes are discovered, Dorsomorphin's selectivity and reversibility make it an ideal probe for dissecting transient or context-dependent events.

Recent comparative reviews (see "Dorsomorphin (Compound C): Precision AMPK and BMP Inhibition") emphasize its evolving role in translational research, particularly where pathway crosstalk underpins disease mechanisms. Whether in cancer metabolism, iron overload disorders, or neural differentiation, Dorsomorphin (Compound C) remains at the forefront of experimental design.

Data-Driven Insights

• Ki for AMPK: 109 nM; IC₅₀ for BMP4-induced SMAD phosphorylation: 0.47 μM.
• Reduces ACC phosphorylation by 80%, providing robust metabolic pathway suppression.
• Effective in vivo at 10 mg/kg (i.p.), demonstrably lowering hepatic hepcidin mRNA and increasing serum iron.

For researchers seeking an integrated approach to dissecting AMPK and BMP/Smad pathways, or for those advancing protocols in autophagy regulation, iron metabolism, and stem cell fate, Dorsomorphin (Compound C) offers unmatched precision and experimental flexibility.